08/19/2025
3:30 PM | Coya Therapeutics (Filer)
| Form 424B7 | |
08/12/2025
7:34 AM | Coya Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
08/12/2025
7:06 AM | Coya Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/12/2025
7:08 AM | Coya Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
07/01/2025
7:00 AM | Coya Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/26/2025
4:00 PM | Coya Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/16/2025
4:05 PM | Coya Therapeutics (Filer)
| Form DEFA14A | |
05/16/2025
4:10 PM | Coya Therapeutics (Filer)
| Form ARS | |
05/13/2025
7:07 AM | Coya Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/13/2025
7:14 AM | Coya Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
04/28/2025
4:07 PM | Coya Therapeutics (Filer)
| Form 10-K/A | |
Get the Latest News and Ratings for COYA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Coya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
03/18/2025
7:26 AM | Coya Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/18/2025
7:20 AM | Coya Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/25/2025
8:30 PM | Coya Therapeutics (Issuer)
ROSS WILBUR L JR (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/25/2025
8:30 PM | Coya Therapeutics (Issuer)
Weinand Dieter (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/25/2025
8:30 PM | Coya Therapeutics (Issuer)
GOLDSTEIN DOV A MD (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/25/2025
8:30 PM | Coya Therapeutics (Issuer)
Villalobos Anabella (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/25/2025
8:30 PM | Coya Therapeutics (Issuer)
Lee Ann (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/10/2025
7:35 AM | Coya Therapeutics (Subject)
HIRSCHMAN ORIN (Filed by)
| Form SCHEDULE 13G/A | |
01/13/2025
7:00 AM | Berman Howard (Reporting)
Coya Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/13/2025
7:00 AM | Coya Therapeutics (Issuer)
Grossman Fred (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/13/2025
7:00 AM | Coya Therapeutics (Issuer)
Swaminathan Arun (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/13/2025
7:00 AM | Coya Therapeutics (Issuer)
SNYDER DAVID S (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/03/2025
8:30 PM | Coya Therapeutics (Issuer)
Weinand Dieter (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/03/2025
8:30 PM | Coya Therapeutics (Issuer)
Villalobos Anabella (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/03/2025
8:30 PM | Coya Therapeutics (Issuer)
Lee Ann (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/03/2025
8:30 PM | Coya Therapeutics (Issuer)
ROSS WILBUR L JR (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/03/2025
8:31 PM | Coya Therapeutics (Issuer)
GOLDSTEIN DOV A MD (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/01/2024
11:15 PM | Coya Therapeutics (Filer)
| Form EFFECT | |
11/29/2024
3:15 PM | Coya Therapeutics (Filer)
| Form 424B3 | |
11/20/2024
4:15 PM | Coya Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
11/14/2024
5:08 PM | Coya Therapeutics (Issuer)
SNYDER DAVID S (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/12/2024
2:37 PM | Coya Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
11/06/2024
7:06 AM | Coya Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/06/2024
7:02 AM | Coya Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/05/2024
4:02 PM | Coya Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/04/2024
12:27 PM | Coya Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
11/04/2024
10:42 AM | Coya Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
10/31/2024
3:42 PM | Coya Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/29/2024
7:00 AM | Coya Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/22/2024
8:08 AM | Coya Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
New law could create $3.7 trillion tsunami. (Ad) During a meeting in Washington D.C., Jeff Brown discovered a bold initiative.
He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard.
The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.”
Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%. You can watch it right here. |
MarketBeat All Access